ENDPOINTS

Early-stage investor Syncona readjusts priorities due to bleak biotech market

The desolate biotech financing environment is starting to take a toll on investment funds, with the UK life sciences firm Syncona announcing it is realigning its priorities. Syncona will look for ways in which existing ...

Jun 20, 2025 - 15:20
 0
Early-stage investor Syncona readjusts priorities due to bleak biotech market
The desolate biotech financing environment is starting to take a toll on investment funds, with the UK life sciences firm Syncona announcing it is realigning its priorities. Syncona will look for ways in which existing ...
Read More

Tags:

Previous Article

AI model developed to unlock the potential of satellite imagery for land cover m...

Next Article

FDA OKs new label expansions for Dupixent and Incyte's Monjuvi

Related Posts

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Phase 3 or bust: Why Lilly won't run mid-stage cancer t...

Jun 2, 2025  0

Patient dies in Rocket gene therapy trial; Lilly’s $1B deal for a non-opioid pain biotech; A new dawn for psychedelics?; and more

Patient dies in Rocket gene therapy trial; Lilly’s $1B ...

May 31, 2025  0

Lilly posts encouraging early-stage weight loss data on amylin candidate

Lilly posts encouraging early-stage weight loss data on...

Jun 16, 2025  0